Background-Acute kidney injury (AKI) is associated with early mortality after percutaneous coronary revascularization procedures, but its prognostic relevance to long-term clinical outcomes remains controversial. Methods and Results-We conducted a retrospective study of 14 782 adults who received coronary angiography in the province of Alberta, Canada, between 2004 and 2006. AKI was identified on the basis of changes in serum creatinine concentration within 7 days of the procedure according to AKI Network criteria. The associations between AKI and long-term outcomes, including mortality, end-stage renal disease, and cardiovascular and renal hospitalizations, were studied with the use of Cox regression of multiple failure times. The adjusted risk of death increased with increasing severity of AKI; compared with no AKI, the adjusted hazard ratio for death was 2.00 (95% confidence interval, 1.69 to 2.36) with stage 1 AKI and 3.72 (95% confidence interval, 2.92 to 4.76) with stage 2 or 3 AKI. The adjusted risk of end-stage renal disease requiring renal replacement therapy also increased according to the severity of AKI (hazard ratio, 4.15 [95% confidence interval, 2.32 to 7.42] and 11.74 [95% confidence interval, 6.38 to 21.59], respectively), as did the risks of subsequent hospitalizations for heart failure and acute renal failure. Conclusions-These findings inform the controversy surrounding AKI after angiography, demonstrating that it is a significant risk factor for long-term mortality, end-stage renal disease, and hospitalization for cardiovascular and renal events after coronary angiography. (Circulation. 2011;123:409-416.)
Clinical Perspective on p 416
Despite these observations, the true long-term clinical consequences of AKI after coronary angiography have remained controversial in light of observations that death after AKI is often complicated by other acute conditions not mediated by AKI, including cardiogenic shock, sepsis, respiratory failure, and bleeding. 6, 11 Conversely, emerging associ-ations between kidney function and cardiovascular disease suggest that it is plausible that kidney injury may contribute to cardiovascular morbidity and mortality in addition to kidney failure after coronary angiography. 5, 11, 12 Although it is known that patients who develop AKI are at increased risk of death after coronary angiography, 6, 13 little is known about the associations between AKI and specific cardiovascular and renal events. These associations are particularly relevant because preexisting kidney disease is common in patients with cardiovascular disease and among patients who develop AKI 14, 15 and because subsequent hospitalizations for cardiovascular events and kidney failure lead to adverse health consequences and high costs.
The purpose of this study was to examine the associations between AKI and long-term clinical outcomes (including death, progression to end-stage renal disease [ESRD] , and hospitalization for cardiovascular and renal events) after coronary angiography. We hypothesized that AKI would be an independent predictor of these outcomes following hospital discharge after adjustment for important cardiovascular and renal prognostic variables, including anatomic location of coronary disease, ejection fraction, baseline glomerular filtration rate, and proteinuria. Furthermore, we hypothesized that these associations would vary with the severity of AKI in a manner dependent on the outcome of interest.
Methods

Study Population
The study cohort was derived retrospectively from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH). APPROACH prospectively collects data on demographic and clinical characteristics on all patients undergoing coronary angiography in the province of Alberta, Canada. 16 Coronary angiography is performed using nonionic iodinated radiocontrast agents with the choice of low-or iso-osmolar radiocontrast agents and use of prophylaxis strategies, including N-acetylcysteine and intravenous fluid, made at the discretion of treating physicians.
The cohort consisted of all Alberta residents Ն18 years of age undergoing coronary angiography from January 1, 2004, to December 31, 2006 . Eligible participants required at least 1 outpatient serum creatinine measurement within a 6-month period before coronary angiography and a subsequent measurement (either inpatient or outpatient) within 7 days after the angiogram. Patients with a renal transplant or who were receiving dialysis before coronary angiography were excluded on the basis of the Northern and Southern Alberta Renal Program registries 17 or by a period of continuous physician billing claims for dialysis. 18
Measurement of Kidney Function
All serum creatinine measurements made in Alberta were obtained from the Alberta Kidney Disease Network repository of laboratory data. 19 Preangiography kidney function was determined with the 4-variable Modification of Diet in Renal Disease Study equation 20 to estimate glomerular filtration rate. 19 AKI was defined on the basis of the change in serum creatinine concentration from the preangiogram level to the peak level observed within 7 days after the coronary angiogram or before coronary artery bypass grafting surgery if the latter was performed within 7 days of angiography. The change in creatinine concentration was calculated using the most recent measurement before the angiogram as the baseline and categorized according to the Acute Kidney Injury Network criteria (AKI stage 1, Ն0.3 mg/dL absolute or 1.5-to 2.0-fold relative increase in serum creatinine; AKI stage 2, Ͼ2to 3-fold increase in serum creatinine; AKI stage 3, Ͼ3-fold increase in serum creatinine or serum creatinine Ն4.0 mg/dL with an acute rise of Ͼ0.5 mg/ dL). 21 Sensitivity analysis was also performed, restricting the analysis to patients with a baseline creatinine measurement within 2 days before the angiogram.
Measurement of Covariates
Age, sex, comorbidity, coronary anatomy (based on Duke myocardial jeopardy score 22 ), left ventricular systolic ejection fraction, and subsequent receipt of coronary revascularization procedures (none, percutaneous coronary intervention, or coronary artery bypass grafting) were determined from the APPROACH database. 16 Provincial laboratory data were used to obtain all quantitative or semiquantitative outpatient urinary protein or albumin measurements collected within 6 months before angiography. 19 Urine protein was categorized as normal, microalbuminuria/proteinuria, or unmeasured 23 on the basis of the most recent preangiography urine specimen for patients with Ͼ1 result available.
Measurement of Outcomes
Participants were followed up for a maximum of 39 months from the date of coronary angiography until death or the study end date (March 31, 2007) . Study end points included death resulting from any cause (as recorded by the Alberta Bureau of Vital Statistics, which maintains records of deaths for all residents of the province of Alberta) and progression to ESRD (identified on the basis of date of registration for chronic dialysis or renal transplantation within one of the Alberta renal programs). 17 Participants were also followed up from the date of hospital discharge until the next cardiovascular hospitalization (with a most responsible diagnosis of MI, heart failure, or cerebrovascular accident), hospitalization with acute renal failure, and hospitalization for any other cause. Cause-specific hospitalizations were identified from provincial hospital discharge records with validated International Classification of Diseases, 9th and 10th revisions, coding algorithms 24 -27 (Table I in 
Statistical Analysis
Differences in baseline characteristics according to AKI stage were compared by the use of ANOVA and 2 tests for continuous and categorical variables, respectively. Pairwise comparisons to the reference group with no AKI were adjusted for multiple comparisons using the Bonferroni correction. Cumulative incidence curves for mortality, ESRD, and first hospitalization for any cause were plotted according to AKI stage. Cox proportional hazards regression was used to model multiple failure times per subject (ie, time to death, ESRD, hospitalization for MI, hospitalization for heart failure, hospitalization for cerebrovascular accident, hospitalization for acute renal failure, and other hospitalizations) as a function of AKI stage, accounting for the correlation in the data through the use of robust variance methods. A competing risk model for correlated unordered events of different type, stratified by outcome type, was fitted under the assumption that the exposure could be associated with repeated events in the same individual. In this model, each outcome can occur once per patient, all patients are at risk for all outcomes, and when a patient experiences 1 outcome, he or she remains at risk for all other outcomes unless death occurs. 28 Participants were censored at the end of follow-up or death. The final model was built looking at single event models to identify stratum-specific effects of exposure and covariates. Covariates considered for adjustment included terms corresponding to the 18 baseline characteristics listed in the Table. Stepwise elimination with backward selection was used to select the most parsimonious set of predictive variables. The proportional hazards assumption for the Cox model was tested and satisfied.
In sensitivity analyses, we repeated models after excluding patients with missing data on proteinuria, severity of coronary artery disease, or left ventricular ejection fraction. All statistical analyses were conducted with STATA (version 11.0; STATA Corp, College Station, TX). The conjoint health research ethics board of the University of Calgary approved the study.
Results
Cohort Formation and Baseline Characteristics
We identified 24 873 Alberta residents Ն18 years of age undergoing coronary angiography during the cohort entry period. We excluded 327 patients receiving renal replacement therapy before study entry, 1105 without a creatinine measurement before coronary angiography, and 8659 patients without a creatinine measurement in the 7 days after coronary angiography ( Figure 1 ). Of the patients without a creatinine measurement within 7 days after angiogram, 8352 (96.4%) were discharged home on the day of the angiogram. The subsequent rates of death, progression to ESRD, and all-cause hospitalization during long-term follow-up were 3.8%, 0.2%, and 45.9%, respectively, in this subgroup. Of the 14 782 participants included in the final cohort, 1099 (7.4%) experienced stage 1 AKI and 321 (2.2%) experienced stage 2 or 3 AKI. These participants were older, had lower preangiography estimated glomerular filtration rate, had proteinuria, and were more likely to have certain comorbidities (including diabetes mellitus, hypertension, and heart failure), lower left ventricular ejection fraction, and more severe coronary artery disease (the Table) . In addition, participants experiencing AKI were less likely to receive percutaneous coronary intervention and more likely to receive coronary artery bypass grafting as a subsequent revascularization procedure.
Unadjusted Rates of Clinical Outcomes by Severity of AKI
Over a median follow-up after discharge of 19.7 months (interquartile range, 10.8 to 28.8 months), 1103 patients (7.5%) died, 93 (0.6%) progressed to ESRD requiring renal replacement therapy, and 6230 (42.1%) were hospitalized. The unadjusted cumulative incidences of death, ESRD, and all-cause hospitalization according to stage of AKI are shown in Figure 2 . The incidence of both mortality and ESRD increased in a graded manner with greater severity of AKI (P for trend Ͻ0.001 for both outcomes). The cumulative incidence of all-cause hospitalization exceeded 40% regardless of AKI status and did not increase in a graded manner with greater severity of AKI (P for trendϭ0.137).
Adjusted Rates of Clinical Outcomes by Severity of AKI
In the adjusted models, AKI remained associated with increases in the risks of death, progression to ESRD, and other cardiovascular and renal-specific hospitalizations (Figure 3 ). Significant differences were present in the strength of associations between AKI stage and the outcome type (P for interaction by strata Ͻ0.001). Compared with those without AKI, the fully adjusted risk of mortality increased 2-fold in those with AKI stage 1 and Ͼ3-fold in those with AKI stage 2 or 3. The adjusted risk of ESRD was most substantially increased in those with AKI stage 2 or 3, in whom a Ͼ11-fold increase in risk was observed. The adjusted risk of hospitalization for MI was 47% greater among those with AKI stage 1, although this risk was not significantly elevated in those with AKI stage 2 or 3. The adjusted risk of hospitalization for heart failure increased by 48% in those with AKI stage 1 and by Ͼ2-fold in those with AKI stage 2 or 3. Hospitalization for cerebrovascular accident was uncommon and was not significantly associated with AKI in adjusted models. Subsequent hospitalizations with AKI were Ͼ2and 3-fold higher in those with stage 1 and stage 2 or 3 AKI, respectively. No significant associations were observed between AKI and the adjusted risk of hospitalization for other causes.
Results were similar when patients without measurements of proteinuria, severity of coronary artery disease, or left ventricular ejection fraction were excluded from the analysis and when the analysis was restricted to patients with a baseline creatinine measurement within 2 days before the angiogram. Rates of adverse outcomes were increased in Figure 3 . Rates and adjusted hazard ratios for all-cause mortality, ESRD, and hospitalization for cardiovascular, renal, and other events according to stage of AKI. AKI defined according to Acute Kidney Injury Network criteria (AKI stage 1, Ն0.3 mg/dL absolute or 1.5-to 2.0fold relative increase in serum creatinine; AKI stage 2, Ͼ2to 3-fold increase in serum creatinine; AKI stage 3, Ͼ3-fold increase in serum creatinine or serum creatinine Ն4.0 mg/dL with an acute rise of Ͼ0.5 mg/dL). Covariates (by stratum) retained in the final model were age (all strata), sex (all strata), diabetes mellitus (all strata), heart failure (all strata), cerebrovascular disease (mortality, MI, cerebrovascular accident, other hospitalization strata), peripheral vascular disease (mortality, MI strata), chronic pulmonary disease (mortality, other hospitalization strata), liver disease (mortality, other hospitalization strata), malignancy (mortality, other hospitalization strata), current smoking (mortality, MI, cerebrovascular accident, other hospitalization strata), acute coronary syndrome (mortality, MI, other hospitalization strata), baseline estimated glomerular filtration rate (all strata), microalbuminuria/proteinuria (all strata), coronary anatomy based on Duke myocardial jeopardy score (mortality, MI, cerebrovascular accident strata), left ventricular ejection fraction (mortality, heart failure, ESRD, acute renal failure, and other hospitalization strata), and coronary revascularization (all strata). HR indicates hazard ratio; CI, confidence interval. those with AKI for participants with chronic kidney disease (preangiography estimated glomerular filtration rate Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ) or without chronic kidney disease before coronary angiography ( Table II in 
Discussion
In this population-based cohort undergoing coronary angiography, the risks of death, progression to ESRD, and subsequent hospitalization for cardiovascular and renal events rose with increasing severity of AKI, although the gradient of risk across stages of AKI differed among these events. Death was a common outcome, and a graded increase in the risk of mortality was observed across the categories of AKI. The risk of subsequent hospitalizations for heart failure and acute renal failure also increased progressively with increasing severity of AKI, whereas the risk of progression to ESRD requiring renal replacement therapy was most substantial in those with the most severe episodes of AKI.
The association between even small changes in serum creatinine and adverse short-term clinical outcomes has been documented repeatedly. 6, 29, 30 Graded increases in mortality within 30 days of coronary angiography and increased length of hospital admission have been shown to correlate with increases in the severity of AKI after coronary angiography. 8 Among patients receiving percutaneous coronary interventions, AKI has been shown to be associated with other early complications, including MI, 5,6 target vessel reocclusion, 5 postprocedural bleeding complications, 6 and the need for mechanical ventilation or circulatory support. 6, 7 The effects of AKI after coronary angiography on longterm adverse cardiovascular and renal events are less clear. Most previous studies of contrast-related AKI have identified events occurring during a short period of follow-up, have not included renal events as outcomes of interest, or were not able to account for important confounders relevant to the risk of future cardiovascular or renal events. 31, 32 Other large cohorts of patients hospitalized with MI (only a minority of whom received coronary procedures) have observed that during long-term follow-up, those with small increases in serum creatinine experienced increased rates of death (up to 19.4 to 27.5 deaths per 100 patient-years), comparable to those observed in our study. 33, 34 Our findings also further extend knowledge about the prognostic implications of AKI after coronary angiography, including its graded associations with subsequent hospitalizations for heart failure and renal failure and with the risk of future progression to ESRD. Although the risk of MI was higher in patients with mild but not severe episodes of AKI, differences in the presentation of acute coronary syndromes in patients with renal insufficiency 35 and competing risks for death may have contributed to this finding.
The associations between AKI and these long-term risks after AKI have several possible explanations. First, patients who develop AKI have a higher prevalence of comorbidities such as diabetes mellitus, heart failure, and chronic kidney disease, each of which may increase the risk of heart failure, progression to kidney failure, and death. 14, 15 However, the strength of the associations that remain after adjustment for important variables related to baseline kidney function and severity of cardiovascular disease suggests that confounding by these characteristics does not completely explain our findings, although we cannot rule out the possibility of residual confounding. Second, AKI may identify patients with impaired cardiac output or renal hemodynamic vulnerability who are at heightened long-term risks for decompensated heart function, loss of kidney function, and death. The long-term risks of adverse outcomes after AKI may be related to long-term effects on kidney function after an episode of AKI. Recent studies suggest that episodes of AKI contribute to persistent loss of kidney function 36, 37 and faster subsequent rate of decline in kidney function, 38, 39 processes that have been associated with future risks of episodes of heart failure 40 and progression to ESRD. 41 Regardless of causality, the occurrence of AKI does appear to accurately identify a group of patients at higher risk for these adverse events, suggesting that targeting these patients for careful outpatient management has the potential to improve long-term outcomes.
These findings are important because a number of therapeutic interventions have been shown to be of value in improving survival, slowing the progression to ESRD, and preventing hospital admissions in general populations of patients with chronic kidney disease 42 or heart failure. 43, 44 Early clinical follow-up, evaluation of volume status, use of diuretics, and inhibitors of the renin-angiotensin system have the potential to improve these outcomes after an episode of AKI; however, further research is needed to evaluate the role of these therapies specifically in survivors of AKI after coronary angiography.
Our study has several strengths, including a source population of all patients undergoing coronary angiography within a defined geographic region in which all residents had access to province-wide funded health care. Our cohort undergoing coronary angiography was well characterized and included detailed information on important prognostic variables related to severity of cardiovascular disease and kidney disease before angiography. We were able to adjust for these important confounders as they related to each of the outcomes of interest in our modeling process.
Our study also has limitations. First, because this study was conducted as a historical cohort study using clinical data, participant selection was limited to patients with clinical concerns or illness that prompted follow-up creatinine measurement within 7 days. Because many patients who were discharged promptly and did not have a follow-up creatinine measurement were excluded, our results may overestimate the overall incidence of these events among all patients undergoing coronary angiography. However, the risks of clinical events in the excluded group without follow-up creatinine measurement were comparable to those in participants without AKI, suggesting that exclusion of these patients is unlikely to have biased estimates of risk relative to the reference group with serum creatinine measurements available but no AKI. Second, episodes of AKI and their severity may have been misclassified owing to our dependence on existing creatinine measurements captured after coronary angiography. However, our approach to identification of AKI is most vulnerable to missing episodes of mild AKI or underestimating the severity of AKI in those who developed it. If such misclassification occurred, we anticipate that it would have attenuated the relative risk of outcomes associated with the moderate or severe forms of AKI. Finally, despite our attempts to control for important confounding variables, residual confounding resulting from unmeasured variables (volume and type of contrast received, use of prophylactic measures, exposure to other nephrotoxins, and the contribution of atheroembolism) or differences in the severity of chronic kidney disease or other comorbidities between groups remains possible. Observational studies of this nature cannot prove that AKI plays a causal role in these outcomes or that prevention of AKI would improve these long-term outcomes. These results should not be interpreted as evidence that patients at risk for AKI should avoid diagnostic and interventional coronary procedures because several studies have documented that patients with kidney disease who do not receive these procedures have poorer outcomes. 45, 46 However, our findings suggest that long-term mortality, ESRD, and cardiovascular and renal hospitalizations would be important outcomes to examine in future randomized trials of interventions targeting postangiography AKI.
Conclusions
Graded increases in the severity of AKI are associated with variation in risks of long-term mortality, progression to ESRD, and hospitalization for cardiovascular and renal events. The presence and severity of AKI after coronary angiography could be used to help identify high-risk patients and to guide further management. Further research focusing on interventions to prevent AKI after coronary angiography should assess the effects on these important clinical outcomes. Strategies to reduce cardiovascular risk and to slow the progression of chronic kidney disease require further study in survivors of radiocontrast-associated AKI. 
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